Summit Therapeutics shares rise 1.40% premarket after announcing Phase III trial data presentation at WCLC 2025.

Summit Therapeutics Inc. rose 1.40% in premarket trading, with the company announcing that data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the International Association for the Study of Lung Cancer's 2025 World Conference on Lung Cancer. This is the second consecutive year ivonescimab has been featured in the WCLC Presidential Symposium.